Can Nanobody Affinity Chromatography Change the Game in AAV8 Purification?

Introduction

Adeno‑associated virus serotype 8 (AAV8) is a gold standard viral vector in gene therapy. However, conventional antibody-based affinity columns suffer from low ligand density, poor stability, and high cost, which limit throughput and product quality. A new study presents a custom nanobody (Nb9) affinity resin that exhibits 9.12 mg ligand/mL, enables clean one-step AAV8 purification, and maintains over 70% binding capacity after 20 purification cycles, challenging the limitations of traditional resins.

Research Highlights

• Ultra-High Ligand Density: The Nb9 nanobody is immobilized on Epoxy-activated agarose, achieving 12 mg of ligand per mL of resin—remarkably higher than most IgG resins.
• Optimized Binding Conditions: Maximum AAV8 capture occurs at pH 7.0 under controlled ionic strength; both lower pH and high salt reduce binding efficiency. This allows flexible buffer design for elution while preserving viral integrity.
• Resin Reusability: After 20 purification cycles, resin retained ~71.9% binding capacity. Even more impressive, after storage at 37 °C for 7 days, loss was only 6%, demonstrating exceptional chemical and thermal stability.
• High Purity Product: SDS-PAGE and ELISA confirm clean AAV8 recovery with minimal host-cell protein contamination—outperforming Protein A/G options and meeting clinical-grade benchmarks.

Future Challenges & Applications

• Tag Expansion: The design principles could be applied to develop custom nanobody resins for capsids of other AAV serotypes, viral antigens, or therapeutic fusion proteins.
• GMP Scale Implementation: The nanobody resin’s chemical robustness under NaOH cleaning makes it well-suited for industrial and clinical manufacturing pipelines.
• Cost-Effective & Sustainable: High reusability reduces resin HDR cost and waste, enabling scalable, continuous downstream workflows.

Conclusion

The Nb9 nanobody-based affinity resin demonstrates how nanobodies can surpass traditional IgG-based columns: offering higher ligand density, consistent AAV8 capture, and binder longevity, all while preserving viral quality. This work represents a promising leap toward smarter, more sustainable viral purification platforms.

Read more about the research: https://www.sciencedirect.com/science/article/pii/S0021967323007331